Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 5Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Multiple Myeloma 3Primary Myelofibrosis 2Oligodendroglioma 2Neuroblastoma 2Myeloproliferative Disorders 2Lymphoma 2Leukemia, Myeloid, Acute 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Thrombocytosis 1Thrombocythemia, Essential 1Sezary Syndrome 1Rhabdomyosarcoma 1Polycythemia Vera 1Polycythemia 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Neuroepithelial 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 32fludarabine phosphate 30Mycophenolic Acid 24Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Peripheral Blood Stem Cell Transplantation 18Methotrexate 18Melphalan 17Filgrastim 17Whole-Body Irradiation 15Cyclosporine 15thymoglobulin 11fludarabine 11Methylprednisolone 11Cytarabine 11Radiotherapy 10Thiotepa 8Granulocyte Colony-Stimulating Factor 8Cord Blood Stem Cell Transplantation 8Stem Cell Transplantation 7Etoposide 6Clofarabine 6Rituximab 5Azacitidine 5Transplantation 4Sirolimus 4Isotretinoin 4Flow Cytometry 4Antibodies 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × imetelstat × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡